Clinical Trials Logo
NCT number NCT01788007
Study type Interventional
Source Taro Pharmaceuticals USA
Contact
Status Completed
Phase Phase 1
Start date January 2013
Completion date December 2013

Clinical Trial Summary

The objective of this study is to compare the relative efficacy and safety of the test formulation Imiquimod 3.75% Topical Cream to the marketed formulation Zyclara® (imiquimod) 3.75% Topical Cream in the treatment of actinic keratosis. Both the test and reference formulations will also be compared to a placebo cream to test for superiority.


Clinical Trial Description

n/a


Study Design

Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment


Related Conditions & MeSH terms


See also
Status Clinical Trial Phase
 Recruiting NCT02866695 - Safety and Efficacy of Ingenol Mebutate Gel 0.015% for Treatment of AK on the Face in Solid Organ Transplant Recipients Phase 4
 Not yet recruiting NCT02867722 - Daylight Photodynamic Therapy for the Treatment of Actinic Keratoses in the Northeast United States N/A
 Recruiting NCT02674048 - Metvix Daylight PDT in Actinic Keratosis N/A
 Recruiting NCT02421471 - PMS to Evaluate the Safety and Efficacy of Picato® Gel N/A
 Completed NCT02239679 - Controlled Study of the Occurrence of Actinic Keratosis on the Face After Cryotherapy + ALA Photodynamic Therapy Phase 2
 Completed NCT01966120 - Safety and Efficacy Study for the Field-directed Treatment of Actinic Keratosis With Photodynamic Therapy Phase 3
 Completed NCT01686152 - Study Comparing Imiquimod Cream, 3.75% to Zyclara® (Imiquimod) Cream, 3.75% in the Treatment of Actinic Keratosis Phase 3
 Active, not recruiting NCT01525329 - Combination Therapy With 5-FU and PDT for the Treatment of Post-transplant Premalignant Skin Disease Phase 3
 Completed NCT01449513 - PEP005 Gel - Biological Effects in Actinic Keratosis Assessed by Reflectance Confocal Microscopy Phase 1
 Completed NCT01444989 - Development and Validation of a Quality of Life Instrument for Actinic Keratosis N/A
 Terminated NCT01203878 - Treatment of Actinic Keratoses of the Face With Imiquimod 3.75% Cream Followed by Photodynamic Therapy Phase 4
 Completed NCT00989313 - A Long Term Follow up Study of Patients Who Have Complete Clearance of Their Actinic Keratosis (AK) Lesions at the Day 57 Visit in the PEP005-028 Study Phase 3
 Completed NCT00306800 - Metvix PDT Versus Vehicle PDT With Aktilite CL128 Lamp in Patients With Actinic Keratosis on the Face and Scalp Phase 3
 Completed NCT00375739 - Study to Determine the Safety of PEP005 0.025% and 0.05% Topical Gel in Patients With Actinic Keratoses Phase 2
 Recruiting NCT02952898 - Study Comparing GDC 695 and Diclofenac Sodium Gel, 3% in Subjects With Actinic Keratoses Phase 1
 Recruiting NCT02878382 - Potential Impact of Patient Vitamin D Status in AK Response to MAL-PDT N/A
 Recruiting NCT02902822 - Tele-dermatology of Skin Cancer in a Cohort of Local Health Authority Employees in the Province of Bergamo Phase 2
 Not yet recruiting NCT02938715 - Pilot Study of the Pragmatic Use of Mobile Phone Based Follow up of Actinic Keratoses Treated With Topical 5-fluorouracil N/A
 Active, not recruiting NCT02611804 - A Randomized, Double-Blind, Parallel-Group, Vehicle-Controlled, Multicenter Study Comparing Diclofenac Sodium Gel, 3% to Solaraze® Gel, 3% in the Treatment of Actinic Keratosis on the Face or Bald Scalp Phase 3
 Completed NCT02289768 - Study To Evaluate The Efficacy And Safety Of Actikerall® Solution In Patients With Grade I-II Actinic Keratoses Phase 3